Moving toward eliminating drug and chemical safety testing in animals

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.

Patients who received digital education demonstrated a better understanding of their disease and its management

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials

At AAO 2023, Diana Do, MD, spoke with the Ophthalmology Times team about her presentation of the results for the 96-week PHOTON study of aflibercept for diabetic macular oedema

Dr Marco Zarbin emphasises the importance of defining “active disease”

Mark Blecher, MD, spoke with the Ophthalmology Times team about his poster addressing retinal visualisation and patients who have undergone small aperture IOL implantation at this year's American Academy of Ophthalmology meeting

In the clinical trial, Oxurion’s novel PKal Inhibitor, THR-149, did not meet its primary endpoint

Infrastructure across Europe needs a major overhaul to optimise education and patient access in groundbreaking treatments

A patient filed a complaint in June 2019 claiming their medical records had been accessed by an NHS employee

Larger 0.6-mm temporary plug features a tapered edge

Developing technology may offer marked improvements in surgical precision

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Penny Asbell, MD, FACS, presented results from the ARMOR Study

The company received marketing authorisation approval in the EU earlier this year

The endorsement follows FDA approval in the United States this summer

At this year's American Academy of Ophthalmology meeting, the Ophthalmology Times team spoke with Megan Baldwin, MD, founder of Opthea Limited, about the company's ShORe and COAST clinical trials